BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27
• 28
• 29
• 30

• Drug Development

  Akcea Initiates AKCEA-ANGPTL3-LRx Phase II Program in Patients With Rare Hyperlipidemias

  AKCEA-ANGPTL3-LRx is designed to reduce the production of angiopoietin-like 3, or ANGPTL3.

  November 14, 2017

   · 

  8 min read
• Business

  Today’s Jaguar Health Conference Call Moved to 5:45 p.m. Eastern Time

  The call is being hosted to review year-to-date sales figures for Jaguar and Napo Pharmaceuticals.

  November 14, 2017

   · 

  6 min read
• Business

  ImmuCell Announces Financial Results for Third Quarter of 2017

  During the three-month period ended September 30, 2017, total product sales were just over $2 million compared to just under $2 million during the same quarter of 2016.

  November 14, 2017

   · 

  10 min read
• Deals

  Apellis Pharmaceuticals Announces Closing of its Initial Public Offering

  The total gross proceeds to Apellis were approximately $150.0 million, before deducting underwriting discounts and commissions and expenses payable by Apellis.

  November 14, 2017

   · 

  2 min read
• GN Store Nord: Transactions in Relation to Share Buyback Program - Nov. 14, 2017

  The share buyback program has been initiated in order to reduce the company’s share capital and to cover obligations under the long-term incentive program.

  November 14, 2017

   · 

  2 min read
• Pharm Country

  DiamiR Announces Publication of Data on microRNA Biomarkers for Neurodegenerative Diseases in Alzheimer’s Research & Therapy

  The study reported in the publication was conducted in collaboration with researchers at Perelman School of Medicine at the University of Pennsylvania.

  November 14, 2017

   · 

  3 min read
• Business

  Abzena Release: Novel Antibodies Against a Ground-Breaking New Target for the Treatment of Cardiovascular Fibrosis Developed by Enleofen Bio, With Support From Abzena, Featured in ‘Nature’ Article

  Abzena plc, the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, works with Enleofen Bio, to develop first-in-class antibody therapeutics for the treatment of fibrotic human diseases.

  November 14, 2017

   · 

  4 min read
• ITL BioMedical Launches ITL Clinical; a New Brand to Target Hospital and Clinical Markets

  ITL BioMedical is pleased to announce the launch of a new global brand, ITL Clinical, that will feature ITL products that serve the hospital and clinical markets.

  November 14, 2017

   · 

  2 min read
• Drug Development

  TapImmune Completes Patient Enrollment Ahead of Schedule in Phase II Cancer Vaccine Study for Treating Triple-Negative Breast Cancer

  The comprehensive four-arm study is designed to help determine the optimal vaccine dose and regimen to maximize the immune response generated against the vaccine’s molecular target, FRa.

  November 14, 2017

   · 

  5 min read
• Drug Development

  Medicenna Presents Clinical Data From Previous Phase I and II Clinical Trials of MDNA55

  The poster presentation by Dr. Bexon provides an overview of the safety and efficacy results from previous Phase I and II clinical trials of the targeted immunotherapy, MDNA55, in 66 patients with recurrent glioblastoma, the most common and deadly form of brain cancer.

  November 14, 2017

   · 

  4 min read